Ligand Pharma (LGND) Tops Q2 EPS by 141c
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $279.44 +6.59%
Revenue Growth %: +33.3%
Financial Fact:
Discontinued operations: 0
Today's EPS Names:
CBRS, MAYS, CRMT, More
Revenue Growth %: +33.3%
Financial Fact:
Discontinued operations: 0
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q2 EPS of $1.81, $1.41 better than the analyst estimate of $0.40. Revenue for the quarter came in at $18.42 million versus the consensus estimate of $17 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- SPS Commerce hires Morgan Stanley to explore sale amid activist push - Reuters
- Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
